Home›Research›Compare›Cagrilintide vs Pramlintide
Peptide ComparisonCagrilintide vs Pramlintide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
Pramlintide
Symlin
Half-life: ~48 minutes
No providers listed yet
Pramlintide is FDA-approved, while Cagrilintide is investigational — the clearest structural difference between them.
Cagrilintide
Half-life
~7 days
Pramlintide
Half-life
~48 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Cagrilintide |
| Further along in FDA review | Pramlintide |
| Less frequent dosing (longer half-life) | Cagrilintide |
| More provider options (21 vs 0) | Cagrilintide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cagrilintide
Pramlintide
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
Pramlintide
Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…
Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Pramlintide
Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Pramlintide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Cagrilintide
Pramlintide
Not enough vendor pricing yet.
Where to source these peptides
Cagrilintide
21 listed
Browse directory →
Providers offeringPramlintide
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Pramlintide — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/pramlintide